All In Biotech

Drug Trial Radar · NCT05387525

A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp

A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or Scalp

Last checked: Nov 20, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 447 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

447

Actual

Start

Oct 24, 2022

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Almirall, S.A.Industry
Sponsor type
Industry
First posted
May 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the incidence of biopsy confirmed invasive squamous cell carcinoma (SCC) in the selected treatment field (TF) after administration of topical tirbanibulin 10 milligram (mg)/gram (g) ointment or diclofenac sodium 3 percent (%) gel over the 3-year study period.

Conditions

  • Keratosis, Actinic

Interventions

  • Tirbanibulin (Klisyri®) 10 mg/g ointmentDrug

    Participants will apply tirbanibulin 10 mg/g ointment topically for 5 days over 25 cm\^2 of the face or scalp with Actinic Keratosis (AK).

  • Diclofenac Sodium 3% GelDrug

    Participants will apply diclofenac dodium 3% gel twice daily for 60 to 90 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Histologically Confirmed Invasive Squamous Cell Carcinoma (SCC) in the Treatment Field (TF)Time frame: Up to 3 years

Locations

49 sites in 6 countries. Site status is shown where the registry gives one.

  • Almirall Investigation Site 102

    Lille, France

  • Almirall Investigation Site 103

    Marseille, France

  • Almirall Investigation Site 104

    Nice, France

  • Almirall Investigational Site 106

    Paris, France

  • Almirall Investigational Site 105

    Rouen, France

  • Almirall Investigational Site 101

    Saint-Priest-en-Jarez, France

  • Almirall Investigational Site 205

    Augsburg, Germany

  • Almirall Investigational Site 211

    Bad Bentheim, Germany

  • Almirall Investigation Site 201

    Bochum, Germany

  • Almirall Investigational Site 214

    Bochum, Germany

  • Almirall Investigational Site 212

    Bonn, Germany

  • Almirall Investigational Site 208

    Detmold, Germany

  • Almirall Investigational Site 210

    Dresden, Germany

  • Almirall Investigational Site 204

    Erlangen, Germany

  • Almirall Investigational Site 206

    Hamburg, Germany

  • Almirall Investigational Site 213

    Hamburg, Germany

  • Almirall Investigational Site 207

    Marburg, Germany

  • Almirall Investigational Site 209

    Merzig, Germany

  • Almirall Investigation Site 202

    Recklinghausen, Germany

  • Almirall Investigational Site 309

    Arezzo, Italy

  • Almirall Investigational Site 302

    Brescia, Italy

  • Almirall Investigational Site 304

    Genova, Italy

  • Almirall Investigational Site 308

    Modena, Italy

  • Almirall Investigational Site 301

    Naples, Italy

  • Almirall Investigational Site 303

    Reggio Emilia, Italy

  • Almirall Investigational Site 305

    Roma, Italy

  • Almirall Investigational Site 306

    Roma, Italy

  • Almirall Investigational Site 307

    Roma, Italy

  • Almirall Investigational Site 310

    Rozzano, Italy

  • Almirall Investigational Site 403

    Lublin, Poland

  • Almirall Investigational Site 406

    Rzeszów, Poland

  • Almirall Investigational Site 407

    Warsaw, Poland

  • Almirall Investigational Site 401

    Wroclaw, Poland

  • Almirall Investigational Site 402

    Wroclaw, Poland

  • Almirall Investigational Site 502

    Barcelona, Spain

  • Almirall Investigational Site 508

    Barcelona, Spain

  • Almirall Investigational Site 510

    Barcelona, Spain

  • Almirall Investigational Site 507

    Granada, Spain

  • Almirall Investigational Site 509

    Granada, Spain

  • Almirall Investigational Site 503

    Madrid, Spain

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.